Analyst Price Target is $97.50
▲ +73.21% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $97.50, with a high forecast of $103.00 and a low forecast of $90.00. The average price target represents a 73.21% upside from the last price of $56.29.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in Krystal Biotech. This Buy consensus rating has held steady for over two years.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.